Paper34400331
Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.
Baik AD and 21 others. Mol Ther, 2021. Cited by 14 papers, by iCite.
Cite this record
ConductScience Library. Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies. Papers, record 34400331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34400331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glycogen Storage Disease Type II | Major topic |
| Lysosomal Storage Diseases | Major topic |
| Animals | |
| Enzyme Replacement Therapy | |
| Hydrolases | |
| Lysosomes | |
| Mice | |
| Tissue Distribution | |
| alpha-Glucosidases |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25613900 | Proteomics. Tissue-based map of the human proteome. | Science | 2015 | https://conductscience.org/library/papers/25613900 | PubMed |
| 2 | 9668092 | Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9668092 | PubMed |
| 3 | 27896120 | Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. | Mol Genet Metab Rep | 2014 | https://conductscience.org/library/papers/27896120 | PubMed |
| 4 | 28874182 | Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. | Acta Neuropathol Commun | 2017 | https://conductscience.org/library/papers/28874182 | PubMed |
| 5 | 24706856 | Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24706856 | PubMed |
| 6 | 8126096 | Expression of alpha 7 integrin cytoplasmic domains during skeletal muscle development: alternate forms, conformational change, and homologies with serine/threonine kinases and tyrosine phosphatases. | J Cell Sci | 1993 | https://conductscience.org/library/papers/8126096 | PubMed |
| 7 | 21397538 | Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. | Mol Genet Metab | 2011 | https://conductscience.org/library/papers/21397538 | PubMed |
| 8 | 23060045 | Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. | Genet Med | 2013 | https://conductscience.org/library/papers/23060045 | PubMed |
| 9 | 22538254 | The emerging phenotype of long-term survivors with infantile Pompe disease. | Genet Med | 2012 | https://conductscience.org/library/papers/22538254 | PubMed |
| 10 | 24954473 | Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. | Mol Ther | 2014 | https://conductscience.org/library/papers/24954473 | PubMed |
| 11 | 22970722 | Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. | Annu Rev Genomics Hum Genet | 2012 | https://conductscience.org/library/papers/22970722 | PubMed |
| 12 | 22266136 | Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. | Mol Genet Metab | 2012 | https://conductscience.org/library/papers/22266136 | PubMed |
| 13 | 18500944 | Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. | Hum Gene Ther | 2008 | https://conductscience.org/library/papers/18500944 | PubMed |
| 14 | 25537451 | Therapies for the bone in mucopolysaccharidoses. | Mol Genet Metab | 2015 | https://conductscience.org/library/papers/25537451 | PubMed |
| 15 | 30291246 | Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. | Nat Commun | 2018 | https://conductscience.org/library/papers/30291246 | PubMed |
| 16 | 23188827 | Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice. | J Biol Chem | 2013 | https://conductscience.org/library/papers/23188827 | PubMed |
| 17 | 17680664 | Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. | Biotechnol Bioeng | 2008 | https://conductscience.org/library/papers/17680664 | PubMed |
| 18 | 11278916 | The integrin alpha 7 cytoplasmic domain regulates cell migration, lamellipodia formation, and p130CAS/Crk coupling. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11278916 | PubMed |
| 19 | 15520017 | Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15520017 | PubMed |
| 20 | 31392203 | Challenges in treating Pompe disease: an industry perspective. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31392203 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41491260 | Assessment of Immune Responses Against AAV Encoded Transgene Products. | AAPS J | 2026 | https://conductscience.org/library/papers/41491260 | PubMed |
| 40268518 | Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40268518 | PubMed |
| 39134822 | Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy. | Mol Diagn Ther | 2024 | https://conductscience.org/library/papers/39134822 | PubMed |
| 38543765 | Using an In Vivo Mouse Model to Determine the Exclusion Criteria of Preexisting Anti-AAV9 Neutralizing Antibody Titer of Pompe Disease Patients in Clinical Trials. | Viruses | 2024 | https://conductscience.org/library/papers/38543765 | PubMed |
| 38033727 | Bringing enzymes to the proximity party. | RSC Chem Biol | 2023 | https://conductscience.org/library/papers/38033727 | PubMed |
| 37759559 | Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37759559 | PubMed |
| 36969713 | Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. | Curr Treat Options Neurol | 2022 | https://conductscience.org/library/papers/36969713 | PubMed |
| 36657645 | Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders. | Adv Drug Deliv Rev | 2023 | https://conductscience.org/library/papers/36657645 | PubMed |
| 35787971 | A rapid and non-invasive proteomic analysis using DBS and buccal swab for multiplexed second-tier screening of Pompe disease and Mucopolysaccharidosis type I. | Mol Genet Metab | 2022 | https://conductscience.org/library/papers/35787971 | PubMed |
| 35203513 | Gene Therapy Developments for Pompe Disease. | Biomedicines | 2022 | https://conductscience.org/library/papers/35203513 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34400331
GET https://conductscience.org/api/papers/v1/34400331/authors?page=2